您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > (±)-Sitagliptin-d4(hydrochloride)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
(±)-Sitagliptin-d4(hydrochloride)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
(±)-Sitagliptin-d4(hydrochloride)图片
规格:98%
分子量:447.8
包装与价格:
包装价格(元)
500ug电议
1mg电议

产品介绍
A neuropeptide with diverse biological activities
货号:ajcx20884
CAS:N/A
分子式:C16H11D4F6N5O.HCl
分子量:447.8
溶解度:Water: Soluble
纯度:98%
存储:Store at -20°C
库存:现货

Background:

(±)-Sitagliptin-d4is intended for use as an internal standard for the quantification of sitagliptin by GC- or LC-MS. Sitagliptin is a mixture of the dipeptidyl peptidase 4 (DPP-4) inhibitor (-)-sitagliptin and (+)-sitagliptin, also known as sitagliptin impurity E, a potential impurity found in commercial preparations of (-)-sitagliptin.1(-)-Sitagliptin is a potent inhibitor of DPP-4 (IC50= 18 nM).2It is selective for DPP-4 over DPP-8 (IC50= 48 µM) as well as several other peptidases, including DPP-9, DPP-2, and amino peptidase P.2,3(-)-Sitagliptin improves glucose tolerance in insulin-resistant Zucker fatty and high-fat diet fed rats as well asob/oband high-fat diet fed mice.4It also reduces hyperglycemia in mice fed a high-fat diet with diabetes induced by streptozotocin . Formulations containing (-)-sitagliptin have been used in the treatment of type 2 diabetes mellitus.


1.Kothari, H.M., Dave, M.G., Pandey, B., et al.Process for preparation of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-α]pyrazin-7(8H)-yl]-L-(2,4,5-trifluorophenyl)butan-2-amine and new impurities in preparation thereof(2013) 2.Biftu, T., Feng, D., Qian, X., et al.(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesBioorg. Med. Chem. Lett.17(1)49-52(2007) 3.Kim, D., Kowalchick, J.E., Edmondson, S.D., et al.Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIAT (sitagliptin phosphate)Bioorg. Med. Chem. Lett.17(12)3373-3377(2007) 4.AhrÉn, B.DPP-4 inhibitorsBest Pract.Res.Clin.Endocrinol.Metab.21(4)517-533(2007)